胃食管交界部腺癌-话题@MedSci

#胃食管交界部腺癌#

3篇内容 | 925人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2254988, encodeId=b88c225498852, content=<a href='/topic/show?id=0c6b8340307' target=_blank style='color:#2F92EE;'>#胃食管交界部腺癌#</a> <a href='/topic/show?id=9e52103953a4' target=_blank style='color:#2F92EE;'>#舒格利单抗#</a>, objectTitle=沈琳教授和张小田教授团队研究荣登JAMA | 助力全球首个PD-L1单抗获批用于胃/胃食管交界部腺癌, objectType=article, longId=865942, objectId=4eed865942df, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=4eed865942df, replyNumber=0, likeNumber=18, createdTime=2025-03-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=4eed865942df, moduleTitle=沈琳教授和张小田教授团队研究荣登JAMA | 助力全球首个PD-L1单抗获批用于胃/胃食管交界部腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eed865942df)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2173992, encodeId=511421e3992dd, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a> <a href='/topic/show?id=0c6b8340307' target=_blank style='color:#2F92EE;'>#胃食管交界部腺癌#</a>, objectTitle=读书报告 | DESTINY-Gastric02研究：德曲妥珠单抗治疗含曲妥珠单抗方案失败的欧美Her2阳性晚期胃癌和胃食道结合, objectType=article, longId=804378, objectId=92848043e8f1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/type2diabetes-s2-stomach-and-pancreas.jpg, objectUrl=/article/show_article.do?id=92848043e8f1, replyNumber=0, likeNumber=87, createdTime=2023-12-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=92848043e8f1, moduleTitle=读书报告 | DESTINY-Gastric02研究：德曲妥珠单抗治疗含曲妥珠单抗方案失败的欧美Her2阳性晚期胃癌和胃食道结合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92848043e8f1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1809335, encodeId=4daa1809335d9, content=<a href='/topic/show?id=0c6b8340307' target=_blank style='color:#2F92EE;'>#胃食管交界部腺癌#</a>, objectTitle=LANCET ONCOL:《柳叶刀》子刊公布FLOT4总生存结果：局部晚期胃或胃食管交界部腺癌围术期化疗FLOT优于ECF/ECX, objectType=article, longId=164686, objectId=6f471646868d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f471646868d, replyNumber=0, likeNumber=83, createdTime=2019-08-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f471646868d, moduleTitle=LANCET ONCOL:《柳叶刀》子刊公布FLOT4总生存结果：局部晚期胃或胃食管交界部腺癌围术期化疗FLOT优于ECF/ECX, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f471646868d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1809333, encodeId=22a7180933363, content=<a href='/topic/show?id=0c6b8340307' target=_blank style='color:#2F92EE;'>#胃食管交界部腺癌#</a>, objectTitle=JAMA Oncol：Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, objectType=article, longId=132933, objectId=f4c613293337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4c613293337, replyNumber=0, likeNumber=85, createdTime=2018-11-01, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4c613293337, moduleTitle=JAMA Oncol：Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4c613293337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1809334, encodeId=71d118093340f, content=<a href='/topic/show?id=0c6b8340307' target=_blank style='color:#2F92EE;'>#胃食管交界部腺癌#</a>, objectTitle=JAMA Oncology:Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, objectType=article, longId=132959, objectId=eade13295914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eade13295914, replyNumber=0, likeNumber=104, createdTime=2019-01-12, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eade13295914, moduleTitle=JAMA Oncology:Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eade13295914)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

胃食管交界部腺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#胃食管交界部腺癌# #舒格利单抗#

沈琳教授和张小田教授团队研究荣登JAMA | 助力全球首个PD-L1单抗获批用于胃/胃食管交界部腺癌

2025-03-07发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期胃癌# #胃食管交界部腺癌#

读书报告 | DESTINY-Gastric02研究：德曲妥珠单抗治疗含曲妥珠单抗方案失败的欧美Her2阳性晚期胃癌和胃食道结合

2023-12-10发表于上海

hb2008ye (审核中...)

前往app查看评论内容

#胃食管交界部腺癌#

LANCET ONCOL:《柳叶刀》子刊公布FLOT4总生存结果：局部晚期胃或胃食管交界部腺癌围术期化疗FLOT优于ECF/ECX

2019-08-18

hb2008ye (审核中...)

前往app查看评论内容

#胃食管交界部腺癌#

JAMA Oncol：Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望

2018-11-01

hb2008ye (审核中...)

前往app查看评论内容

#胃食管交界部腺癌#

JAMA Oncology:Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望

2019-01-12

科室
- - 订阅+
  - 更多科室
工具
服务